4-aminopyridine has been researched along with Ataxia in 9 studies
Ataxia: Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The therapeutic effects of 4-aminopyridine (4AP) were investigated in a randomized, double-blind, crossover trial in 10 subjects with familial episodic ataxia with nystagmus." | 9.15 | A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. ( Adrion, C; Brandt, T; Claassen, J; Dichgans, M; Freilinger, T; Jahn, K; Jen, JC; Jurkat-Rott, K; Kalla, R; Klopstock, T; Lehmann-Horn, F; Mansmann, U; Neugebauer, H; Spiegel, R; Strupp, M, 2011) |
| "Patients with episodic ataxia type 2 (EA2) can often be successfully treated with acetazolamide." | 9.11 | Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. ( Brandt, T; Dichgans, M; Freilinger, T; Glasauer, S; Kalla, R; Strupp, M, 2004) |
| "Episodic ataxia type 2 is an autosomal dominant channelopathy, caused by genetic variants in the voltage-dependent calcium channel a-1 subunit (CACNA1A), which is characterized by intermittent episodes of vertigo and ataxia." | 5.72 | The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2. ( Brieva-Ruiz, L; González-Mingot, C; López-Ortega, R, 2022) |
| "The therapeutic effects of 4-aminopyridine (4AP) were investigated in a randomized, double-blind, crossover trial in 10 subjects with familial episodic ataxia with nystagmus." | 5.15 | A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. ( Adrion, C; Brandt, T; Claassen, J; Dichgans, M; Freilinger, T; Jahn, K; Jen, JC; Jurkat-Rott, K; Kalla, R; Klopstock, T; Lehmann-Horn, F; Mansmann, U; Neugebauer, H; Spiegel, R; Strupp, M, 2011) |
| "Patients with episodic ataxia type 2 (EA2) can often be successfully treated with acetazolamide." | 5.11 | Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. ( Brandt, T; Dichgans, M; Freilinger, T; Glasauer, S; Kalla, R; Strupp, M, 2004) |
| "Previous theories assumed that the beneficial effect of the potassium channel blocker 4-aminopyridine (4-AP) for patients suffering from downbeat nystagmus (DBN) or episodic ataxia type 2 (EA2) is due to an increase of excitability of cerebellar Purkinje cells (PC)." | 3.77 | The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus. ( Glasauer, S; Rössert, C; Strupp, M, 2011) |
| "Episodic ataxia type 2 is an autosomal dominant channelopathy, caused by genetic variants in the voltage-dependent calcium channel a-1 subunit (CACNA1A), which is characterized by intermittent episodes of vertigo and ataxia." | 1.72 | The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2. ( Brieva-Ruiz, L; González-Mingot, C; López-Ortega, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| González-Mingot, C | 1 |
| López-Ortega, R | 1 |
| Brieva-Ruiz, L | 1 |
| Stahl, JS | 1 |
| Thumser, ZC | 1 |
| Tsunemi, T | 1 |
| Ishikawa, K | 1 |
| Tsukui, K | 1 |
| Sumi, T | 1 |
| Kitamura, K | 1 |
| Mizusawa, H | 1 |
| Goudarzi, I | 1 |
| Kaffashian, M | 1 |
| Shabani, M | 1 |
| Haghdoost-Yazdi, H | 1 |
| Behzadi, G | 1 |
| Janahmadi, M | 1 |
| Strupp, M | 4 |
| Kalla, R | 3 |
| Claassen, J | 2 |
| Adrion, C | 1 |
| Mansmann, U | 1 |
| Klopstock, T | 1 |
| Freilinger, T | 2 |
| Neugebauer, H | 1 |
| Spiegel, R | 2 |
| Dichgans, M | 2 |
| Lehmann-Horn, F | 1 |
| Jurkat-Rott, K | 1 |
| Brandt, T | 2 |
| Jen, JC | 1 |
| Jahn, K | 1 |
| Glasauer, S | 2 |
| Rössert, C | 1 |
| Hess, E | 1 |
| Teufel, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for 4-aminopyridine and Ataxia
| Article | Year |
|---|---|
A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.
Topics: 4-Aminopyridine; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Ataxia; Cal | 2011 |
Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
Topics: 4-Aminopyridine; Acetazolamide; Adolescent; Adult; Ataxia; Calcium Channels; Humans; Male; Middle Ag | 2004 |
7 other studies available for 4-aminopyridine and Ataxia
| Article | Year |
|---|---|
The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2.
Topics: 4-Aminopyridine; Acetazolamide; Adult; Ataxia; Cerebellar Ataxia; Female; Humans; Male; Middle Aged; | 2022 |
4-aminopyridine does not enhance flocculus function in tottering, a mouse model of vestibulocerebellar dysfunction and ataxia.
Topics: 4-Aminopyridine; Animals; Ataxia; Cerebellum; Eye Movements; Mice; Mice, Inbred C57BL; Purkinje Cell | 2013 |
The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.
Topics: 4-Aminopyridine; Amifampridine; Ataxia; Drug Administration Schedule; Female; Genetic Predisposition | 2010 |
In vivo 4-aminopyridine treatment alters the neurotoxin 3-acetylpyridine-induced plastic changes in intrinsic electrophysiological properties of rat cerebellar Purkinje neurones.
Topics: 4-Aminopyridine; Animals; Ataxia; Behavior, Animal; Drug Interactions; Electrophysiological Phenomen | 2010 |
The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus.
Topics: 4-Aminopyridine; Animals; Ataxia; Computer Simulation; Disease Models, Animal; Electrophysiological | 2011 |
A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.
Topics: 4-Aminopyridine; Ataxia; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Nystag | 2011 |
Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study.
Topics: 4-Aminopyridine; Adult; Ataxia; Calcium Channels; Humans; Male; Middle Aged; Nystagmus, Pathologic; | 2013 |